Literature DB >> 8088621

Epithelioid sarcoma of the Bartholin's gland primarily diagnosed as vulvar carcinoma.

T Konefka1, E Senkus, J Emerich, M Dudziak.   

Abstract

A case of vulvar epithelioid sarcoma (VES) in a 49-year-old female is described. The disease originated from Bartholin's gland and was originally diagnosed as vulvar squamous cell carcinoma. The patient was treated by radical vulvectomy and bilateral inguinal lymphadenectomy. Multidrug chemotherapy using doxorubicin, cyclophosphamide, vincristine, and dacarbazine was started, but had to be abandoned because of cardiac toxicity. Despite intensive treatment, the patient developed pulmonary metastatic disease and died after 8 months. The course of epithelioid sarcoma in this site seems to be more aggressive than in typical extremity locations and was consistent with other cases described in the literature.

Entities:  

Mesh:

Year:  1994        PMID: 8088621     DOI: 10.1006/gyno.1994.1231

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Clinical Pathology of Bartholin's Glands: A Review of the Literature.

Authors:  Min Y Lee; Amanda Dalpiaz; Richard Schwamb; Yimei Miao; Wayne Waltzer; Ali Khan
Journal:  Curr Urol       Date:  2015-05-20

2.  Epithelioid sarcoma of the vulva in a 17-year-old pregnant woman.

Authors:  Har Rai; Kunle Odunsi; Joshua Kesterson; Carl Morrison; Ada Chan; Paulette Mhawech-Fauceglia
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-05

Review 3.  Vulvar "proximal-type" epithelioid sarcoma: report of a case and review of the literature.

Authors:  Lodovico Patrizi; Giacomo Corrado; Maria Saltari; Letizia Perracchio; Chiara Scelzo; Emilio Piccione; Enrico Vizza
Journal:  Diagn Pathol       Date:  2013-07-25       Impact factor: 2.644

4.  Epithelioid sarcoma of vulva: a case report and review of the literature.

Authors:  Kadri Altundag; Oguz Dikbas; Basak Oyan; Alp Usubutun; Alev Turker
Journal:  Med Oncol       Date:  2004       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.